Radiopharmaceuticals Market to Grow with a CAGR of 5.25% through 2029
Rise in diagnostic imaging procedures
and expansion of therapeutic applications is factors driving the Global
Radiopharmaceuticals Market in the forecast period 2025-2029.
According
to TechSci Research report, “Radiopharmaceuticals Market – Global Industry
Size, Share, Trends, Competition Forecast & Opportunities, 2029”,
the Global Radiopharmaceuticals Market stood at USD 5.52 Billion in 2023 and is
anticipated to grow with a CAGR of 5.25% through 2029. In addition to
diagnostic imaging, radiopharmaceuticals are increasingly being used for
therapeutic applications, driving growth in the global radiopharmaceuticals
market. Therapeutic radiopharmaceuticals deliver targeted radiation therapy to
specific tissues or organs, offering precise and effective treatment options
for a wide range of medical conditions, including cancer, thyroid disorders,
and bone metastases. One of the most significant developments in therapeutic
nuclear medicine is the emergence of targeted radionuclide therapy (TRT), which
involves the administration of radiopharmaceuticals that selectively bind to
tumor cells or disease-specific targets, delivering therapeutic doses of
radiation directly to the site of disease while sparing surrounding healthy
tissues.
Advancements in
radiochemistry, radiopharmaceutical production, and targeted drug delivery
technologies are driving innovation in therapeutic radiopharmaceuticals,
expanding the scope of nuclear medicine in oncology, cardiology, and other therapeutic
areas. The expansion of therapeutic applications presents new opportunities for
growth and market penetration in the global radiopharmaceuticals market, as
healthcare providers seek to leverage the benefits of targeted radiation
therapy for the treatment of a diverse range of diseases and conditions.
Another key trend fueling growth in the
global radiopharmaceuticals market is the increased investments in research and
development (R&D) by pharmaceutical companies, academic institutions, and
government agencies. R&D efforts focus on developing novel
radiopharmaceuticals, improving production processes, and advancing imaging and
therapeutic techniques to address unmet medical needs and enhance patient care.
One area of focus in radiopharmaceutical R&D is the development of novel
PET tracers for imaging specific biomarkers associated with disease
pathophysiology and treatment response. For example, researchers are exploring
the use of radiolabeled ligands targeting amyloid beta and tau proteins in the
brain for the early diagnosis and monitoring of Alzheimer's disease and other
neurodegenerative disorders.
Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Radiopharmaceuticals Market”
The
Global Radiopharmaceuticals Market is segmented into type, source, end user, regional distribution and company.
Based on the source, nuclear reactors is anticipated to bolster in the global
radiopharmaceuticals market. Nuclear reactors play a vital role in the
production of radioisotopes, such as technetium-99m (Tc-99m), which are widely
used in diagnostic imaging procedures. Tc-99m is the most commonly used
radioisotope in nuclear medicine, accounting for a significant portion of
radiopharmaceuticals used in diagnostic imaging studies worldwide. Nuclear reactors provide a reliable and
cost-effective method for large-scale production of Tc-99m and other
radioisotopes through nuclear fission reactions. The availability of nuclear
reactors capable of producing Tc-99m is essential for ensuring a stable supply
of radiopharmaceuticals to meet the growing demand for diagnostic imaging
procedures in healthcare facilities.
North America is anticipated to emerge
as the fastest-growing segment in the global radiopharmaceuticals market. North
America boasts a developed healthcare system with high adoption rates of
advanced diagnostic imaging procedures such as positron emission tomography
(PET) and single-photon emission computed tomography (SPECT), driving demand
for radiopharmaceuticals. Rising investments in research and
development, favorable reimbursement policies, and strategic collaborations
between industry stakeholders are expected to further accelerate market growth
in the region.
Europe is
anticipated to be the second most dominating region in the global
radiopharmaceuticals market. Europe benefits from a strong regulatory
framework, well-established healthcare infrastructure, and increasing
investments in nuclear medicine research. The region has a significant market
presence of key radiopharmaceutical manufacturers and research institutions,
driving innovation and market expansion. Growing applications of
radiopharmaceuticals in oncology, cardiology, and neurology further contribute
to the growth of the European radiopharmaceuticals market.
Major
companies operating in Global Radiopharmaceuticals Market are:
- PharmaLogic Holdings Corp.
- Jubilant Radiopharma
- China lsotope &
Radiation Corporation.
- Siemens Healthcare GmbH
- SHINE Technologies, LLC
- Ion Beam Applications SA
- Global Medical Solutions
- BWX Technologies. Inc
- Coquí Radiopharmaceuticals
Corp.
- Evergreen Theragnostics,
Inc.
Download Free Sample Report
Customers
can also request 10% free customization in this report
“The
Global Radiopharmaceuticals Market is on an upward trajectory, driven by a
combination of technological advancements, demographic shifts, and supportive
government policies. Theranostics, which combines diagnostics and therapy using
radiopharmaceuticals, has gained traction in recent years. This approach allows
for personalized treatment strategies, wherein patients can be diagnosed and
treated based on their individual molecular profiles. Subsequently, The integration
of theranostics in clinical practice is driving market growth by offering more
precise and effective treatment options for patients. As the industry continues
to evolve, further innovations, research breakthroughs, and strategic
collaborations are expected to shape its future landscape, offering promising
prospects for both healthcare providers and patients worldwide.” said Mr. Karan
Chechi, Research Director of TechSci Research, a research-based management
consulting firm.
“Radiopharmaceuticals Market By Type (Diagnostic Radiopharmaceuticals,
Therapeutic Radiopharmaceuticals), By Source (Nuclear Reactors and
Cyclotrons), By End user (Hospitals & Clinics, Diagnostics imaging center, Others), By Region, By Competition Forecast &
Opportunities, 2019-2029F”, has evaluated the future growth potential of Global
Radiopharmaceuticals Market and provides statistics & information on market
size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Global
Radiopharmaceuticals Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New
York, United States- 10170
Tel:
+1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com